Skip to main content
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 1877 ISIN · CNE100003FF7 HKEX Manufacturing
Open in API
Filings indexed 1,740 across all filing types
Latest filing 2025-12-14 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1877

About Shanghai Junshi Biosciences Co., Ltd.

http://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company established in 2012. It is dedicated to the discovery, development, clinical research, and commercialization of innovative therapeutics, prioritizing the creation of first-in-class and best-in-class drugs. The company utilizes a global integrated R&D system and proprietary full life cycle antibody development platform technology to build a diversified and complementary pipeline. Junshi Biosciences operates as a full-chain entity, integrating research, production, and commercialization capabilities to maintain global competitiveness in the biopharmaceutical sector.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-12-14 English
VOLUNTARY ANNOUNCEMENT - FDA APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR JS212
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement issued by Shanghai Junshi Biosciences regarding the FDA approval of an Investigational New Drug (IND) application for a specific drug (JS212). It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding company operations and product development that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-12-14 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING BY ONE OF THE CONTROLLING SHAREHOLDERS, ACTUAL CONTROLLERS AND THE CH
Director's Dealing Classification · 95% confidence The document is an 'Overseas Regulatory Announcement' from Shanghai Junshi Biosciences Co., Ltd. regarding the progress of a shareholding increase by the Chairman and controlling shareholder, Mr. Xiong Jun. It details specific transactions (100,000 A shares purchased) and the status of a previously announced share purchase plan. While it involves a director's shareholding, it is structured as a formal corporate announcement of progress on a capital-related plan rather than a simple notification of a single trade (DIRS). It does not fit the criteria for a report publication announcement (RPA) as it is the primary disclosure of the event itself. Given the nature of the disclosure regarding shareholding changes by a major shareholder/director, it is best classified as a Director's Dealing (DIRS) or a general Regulatory Filing (RNS). However, since it specifically details the progress of a director's share purchase plan, DIRS is the most precise category.
2025-12-10 English
VOLUNTARY ANNOUNCEMENT - NEW INDICATIONS OF TUOYI AND JUNSHIDA HAVE BEEN INCLUDED IN THE NATIONAL REIMBURSEMENT DRUG LIST
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement issued by Shanghai Junshi Biosciences Co., Ltd. regarding the inclusion of its products (TUOYI and JUNSHIDA) in the National Reimbursement Drug List (NRDL). It provides details on the drug indications, medical insurance classification, and the potential impact on the company's business. As it is a general regulatory announcement regarding company operations and product status that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-12-07 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-12-07 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE NEW DRUG APPLICATION FOR ROCONKIBART INJECTION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from Shanghai Junshi Biosciences Co., Ltd. regarding the acceptance of a New Drug Application (NDA) by the National Medical Products Administration for their product, Roconkibart. It details the drug's purpose, clinical trial results, and associated risks. Since this is a regulatory announcement regarding a specific corporate development (drug approval status) that does not fit into financial reporting, dividend, or governance categories, it is classified as a Regulatory Filing (RNS).
2025-12-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.